Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

New Treatment Indications Boost Survival in Metastatic Hormone-Sensitive Prostate Cancer

February 7th 2020

William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.

Dr. Hwang on the Evolution of Treatment in Metastatic CSPC

February 7th 2020

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

Dr. Sartor on Emerging Agents in Prostate Cancer

February 6th 2020

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Education, Collaboration Key to Increasing Genetic Screening in Prostate Cancer

February 5th 2020

Thomas J. Polascik, MD, discusses the growing relevance of genetic testing for men with prostate cancer and those at a high risk of developing the disease.

Dr. Morris on Treatment Considerations for CRPC

February 5th 2020

David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.

Dr. Chang on Adjuvant Versus Salvage Radiation in High-Risk Prostate Cancer

February 4th 2020

Sam S. Chang, MD, MBA, discusses adjuvant versus salvage radiation in patients with nonmetastatic high-risk prostate cancer.

Darolutamide Nears EU Approval for Nonmetastatic CRPC

February 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Darolutamide Improves Survival in Nonmetastatic CRPC

January 30th 2020

Darolutamide plus androgen deprivation therapy (ADT) led to a significant improvement in overall survival (OS) compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer, according to results from a preplanned final OS analysis of the phase III ARAMIS trial.

Dr. Bryce on Ongoing Research Regarding CDK12 Alterations in Prostate Cancer

January 30th 2020

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Dr. Shinohara on Toxicities of Stereotactic Body Radiotherapy in Prostate Cancer

January 30th 2020

Eric Shinohara, MD, MSCI, discusses the toxicities associated with stereotactic body radiotherapy in prostate cancer.

Dr. Oh on the ENZAMET Trial in mHSPC

January 30th 2020

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Apalutamide Approved in Europe for Metastatic Castration-Sensitive Prostate Cancer

January 29th 2020

The European Commission has approved apalutamide for use in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer.

Radiopharmaceuticals Show Signs of Progress in Prostate Cancer

January 29th 2020

A. Oliver Sartor, MD, discusses the development of radiopharmaceuticals in prostate cancer.

Dr. Koo on the Actionability of Next-Generation Imaging Results in Prostate Cancer

January 29th 2020

Phillip J. Koo, MD, division chief of Diagnostic Imaging, Banner MD Anderson Cancer Center, discusses the actionability of next-generation imaging results in prostate cancer.

Dr. Bryce on Ongoing Research in Prostate Cancer

January 29th 2020

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

Dr. Hwang on the State of Treatment in Metastatic Prostate Cancer

January 29th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

Dr. Moses On Ongoing Trials in mHSPC

January 28th 2020

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Dr. Penson on Maintaining QoL With AR Inhibitors in Nonmetastatic CRPC

January 25th 2020

David F. Penson, MD, MPH, MMHC, discusses the importance of maintaining quality of life for patients treated with androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.

Dr. Cheng on Molecular Testing Considerations in Prostate Cancer

January 25th 2020

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Dr. Shinohara on the Future of Radiation and Surgery in Prostate Cancer

January 25th 2020

Eric Shinohara, MD, MSCI, discusses the future of stereotactic body radiation and surgery in prostate cancer.